Investor Relations
TadbeerPharma is building the first science-led, regulatory-capable pharmaceutical platform for Afghanistan. We are open to co-investment, strategic partnership, and development finance engagement.
Underserved Market
Afghanistan's pharmaceutical market is significantly undersupplied. Dozens of essential medicines with proven efficacy remain unregistered — not due to demand failure, but due to the absence of a regulatory-capable operator.
Proprietary Registration Pipeline
Our competitive advantage is the AFDA registration dossier itself. Once a molecule is registered in our name, we hold a structural market position for that therapeutic in Afghanistan — a durable, regulatory moat.
~90% Cost Reduction Potential
By targeting off-patent molecules and working with GMP-certified manufacturers in Bangladesh, India, and Turkey, we achieve cost structures that are a fraction of originator pricing — enabling volume at accessible price points.
Compliance-First Model
Every product we deploy is AFDA-registered, GMP-sourced, and WHO-guideline compliant. This is not a grey-market operation — it is a defensible, institution-grade pharmaceutical business.
Key Metrics
Engage With Our Investment Team
We welcome structured dialogue with healthcare-focused investors, development finance institutions, and strategic partners aligned with advancing regulated pharmaceutical access in Afghanistan.